1. Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA. 2003;290(21):2805-2816. doi:10.1001/jama.290.21.2805 The drugs, order of addition, and recommended doses for each stepof each strategy are summarized. Nonstudy antihypertensive drugs could beadded to control blood pressure except for β-blockers in those assignedto the calcium antagonist strategy and calcium antagonists for those assignedto the non–calcium antagonist strategy. Titration ranges: atenolol,25-200 mg/d; hydrochlorothiazide, 12.5-100 mg/d; trandolapril, 1-8 mg/d; andverapamil sustained release, 120-480 mg/d. *For patients with creatinine levelsof 2.0 mg/dL or higher (≥177 µmol/L), the recommended starting dosewas 0.5 mg/d of trandolapril. Figure Legend:

2. Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA. 2003;290(21):2805-2816. doi:10.1001/jama.290.21.2805

3. Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA. 2003;290(21):2805-2816. doi:10.1001/jama.290.21.2805 There were no significant differences in systolic or diastolic bloodpressure. Figure Legend:

4. Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA. 2003;290(21):2805-2816. doi:10.1001/jama.290.21.2805 The relative risk was 0.98 (95% confidence interval, 0.90-1.06). Figure Legend:

5. Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA. 2003;290(21):2805-2816. doi:10.1001/jama.290.21.2805 CI indicates confidence interval; RR, relative risk. P value from Kaplan-Meier survival analysis. Figure Legend:

6. Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease: The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial JAMA. 2003;290(21):2805-2816. doi:10.1001/jama.290.21.2805 Other race/ethnicity indicates Asian or multiracial. All medicalconditions were present at baseline. CI indicates confidence interval; RR,relative risk. Figure Legend: